AirSculpt Technologies, Inc. (AIRS)
NASDAQ: AIRS · Real-Time Price · USD
2.680
+0.140 (5.51%)
At close: Apr 30, 2026, 4:00 PM EDT
2.700
+0.020 (0.74%)
After-hours: Apr 30, 2026, 7:46 PM EDT

AirSculpt Technologies Earnings Call Transcripts

Fiscal Year 2025

  • Sequential improvement in same-store sales and adjusted EBITDA marked Q4 2025, with new services and enhanced marketing driving stabilization. 2026 guidance anticipates modest revenue growth, continued deleveraging, and no new center openings as focus remains on existing operations.

  • Q3 revenue declined 17.8% year-over-year amid a challenging consumer environment, but cost controls and new GLP-1-related services are positioning the business for future growth. 2025 revenue guidance was lowered, while EBITDA is expected at the low end of prior guidance.

  • The business operates 32 high-end body contouring centers, generating $180 million in 2024 revenue and $21 million adjusted EBITDA. Strategic focus is on same-store growth, marketing efficiency, and new service pilots, with strong cash flow supporting debt reduction and future expansion opportunities.

  • Q2 2025 saw revenue decline 13.7% year-over-year to $44M, with Adjusted EBITDA at $5.8M and improved cost management. Guidance for 2025 is reiterated, with no new centers planned and a focus on same-store sales amid a challenging consumer environment.

  • Q1 2025 saw a 17.3% revenue decline and lower case volumes, but improved marketing efficiency and cost discipline led to sequential EBITDA gains. Guidance for 2025 anticipates $160–$170 million in revenue and a return to same-store sales growth by year-end.

  • The company operates 32 centers with a patented, minimally invasive body contouring procedure and strong brand, targeting an $11 billion market. Despite 2024 revenue and EBITDA declines due to sector headwinds, leadership is focused on transformation through marketing, sales, technology, and expansion.

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Powered by